Neratinib for treating HER2-positive breast cancer after 2 therapies [ID1381]
Discontinued
Reference number: GID-TA10539
The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of neratinib for treating HER2-positive breast cancer after 2 therapies.
Following on from advice from the company, they are currently not in a position to submit all evidence to NICE whilst they consider their regulatory filing strategy, therefore the appraisal has been suspended.
NICE will continue to monitor the situation and provide an update if and when the situation changes.